Tycho Heimbach, Ph.D.

Merck & Co., Inc.

Poster(s):

• (T0930-07-38) Dissolution Bioequivalence Safe Space Assessment of Molnupiravir and NHC Using Physiologically Based Biopharmaceutics Modeling
  Tuesday, October 18, 2022

  9:30 AM – 10:30 AM ET

• (M1330-02-10) Physiological Based Biopharmaceutics Modeling (PBBM) for pH-dependent DDI Risk Identification and Formulation Selection for a Weak Base Compound
  Monday, October 17, 2022

  1:30 PM – 2:30 PM ET